248 related articles for article (PubMed ID: 21037799)
1. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
[TBL] [Abstract][Full Text] [Related]
2. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
3. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
Banerji U; Affolter A; Judson I; Marais R; Workman P
Mol Cancer Ther; 2008 Apr; 7(4):737-9. PubMed ID: 18375819
[TBL] [Abstract][Full Text] [Related]
4. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.
Brandes AH; Ward CS; Ronen SM
Breast Cancer Res; 2010; 12(5):R84. PubMed ID: 20946630
[TBL] [Abstract][Full Text] [Related]
5. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
6. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker.
Aboagye EO
Oncotarget; 2010 Jul; 1(3):163-166. PubMed ID: 21301046
[No Abstract] [Full Text] [Related]
8. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
9. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
10. [Progress in the study of heat shock protein 90 inhibitors].
Luo HM; Sun W; Yin JY; Yang XH
Yao Xue Xue Bao; 2010 Jul; 45(7):813-20. PubMed ID: 20931776
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
14. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
[TBL] [Abstract][Full Text] [Related]
15. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
17. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Pacey S; Gore M; Chao D; Banerji U; Larkin J; Sarker S; Owen K; Asad Y; Raynaud F; Walton M; Judson I; Workman P; Eisen T
Invest New Drugs; 2012 Feb; 30(1):341-9. PubMed ID: 20683637
[TBL] [Abstract][Full Text] [Related]
18. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
19. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.
Fukuyo Y; Inoue M; Nakajima T; Higashikubo R; Horikoshi NT; Hunt C; Usheva A; Freeman ML; Horikoshi N
Cancer Res; 2008 Aug; 68(15):6324-30. PubMed ID: 18676857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
